There are currently 1184 clinical trials in Pittsburgh, Pennsylvania looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Pittsburgh, University of Pittsburgh Medical Center, Alleghany General Hospital and Children's Hospital of Pittsburgh UPMC. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Early Intervention to Promote Cardiovascular Health of Mothers and Children
NCT06272045
Recruiting
Early Intervention to Promote Cardiovascular Health of Mothers and Children (ENRICH) is a cluster randomized clinical trial, funded by the National Heart Lung \& Blood Institute. The study is designed to test the effectiveness of home visiting intervention to promote cardiovascular health and reduce disparities in maternal and early childhood cardiovascular health. Sites, in partnership with evidence-based home visiting programs, are recruiting 6400 participants in total (i.e., 3200 parent-dyads... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/08/2024
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Cardiovascular Health
Register for Updates
Longitudinal ctDNA Surveillance for Older Women With ER+ Breast Cancer Who Omit Surgery
NCT05914792
Recruiting
This prospective study recruits patients with ER+/HER2-, non-metastatic breast cancer who omit upfront surgery in favor of primary endocrine therapy for sample collection and prospective circulating tumor DNA (ctDNA) measurement to guide disease surveillance.
Gender:
FEMALE
Ages:
70 years and above
Trial Updated:
07/07/2024
Locations: UPMC Magee Womens Hospital - Surgical Oncology, Pittsburgh, Pennsylvania
Conditions: Breast Cancer
Register for Updates
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
NCT03391778
Recruiting
This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.
Gender:
ALL
Ages:
All
Trial Updated:
07/02/2024
Locations: University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Neoplasms
Register for Updates
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
NCT04486352
Recruiting
This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening with homogeneous basic eligibility criteria in order to direct study participants into biomarker-matched study cohorts consisting of testing targeted agents.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/02/2024
Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Conditions: Endometrial Cancer
Register for Updates
The Pittsburgh Study Early Childhood
NCT05444205
Recruiting
The Early Childhood Collaborative of The Pittsburgh Study is a community-partnered, county-wide implementation of programs for children and families from birth through formal school entry to address real-world challenges that exist in providing effective preventive interventions for families with young children, particularly low-income families.
Gender:
ALL
Ages:
6 years and below
Trial Updated:
07/01/2024
Locations: Primary Care Health Services, Pittsburgh, Pennsylvania +4 locations
Conditions: Child Development, Child Language, Child Behavior Problem, Parenting, Parent Child Abuse
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Allegheny General Hospital, Pittsburgh, Pennsylvania +11 locations
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
A Study of KER-050 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
NCT04419649
Recruiting
The purpose of this study is to evaluate the effects of KER-050 on anemia in patients with very low, low or intermediate risk MDS.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2024
Locations: University of Pittsburgh Medical Health Center, Pittsburgh, Pennsylvania
Conditions: Myelodysplastic Syndromes, Cytopenia
Register for Updates
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT02817633
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: GSK Investigational Site, Pittsburgh, Pennsylvania
Conditions: Neoplasms
Register for Updates
Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer
NCT05766748
Recruiting
This is an open label study to determine the safety and preliminary evidence of a therapeutic effect of azeliragon in patients refractory to prior treatment of metastatic pancreatic cancer.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/13/2024
Locations: AHN Cancer Institute - Allegheny General Hospital, Pittsburgh, Pennsylvania
Conditions: Metastatic Pancreatic Cancer
Register for Updates
MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach
NCT06050707
Recruiting
The proposed study is a phase II, single arm, open-label trial of MR-guided radiation therapy (RT) with risk stratified RT dose selection in patients with anal cancer. Based on previous data, a risk adaptive treatment approached is proposed in 4 groups: Low risk, standard risk, intermediate risk, and high risk. Human papillomavirus (HPV) DNA will be analyzed to identify novel biomarkers that predict chemoradiotherapy (CRT) response and toxicity.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: Allegheny Health Network, Pittsburgh, Pennsylvania
Conditions: Anal Squamous Cell Carcinoma
Register for Updates
Eliminating Monitor Overuse Trial (EMO Trial)
NCT05132322
Recruiting
The purpose of this study is to identify the optimal deimplementation strategies for an overused practice: continuous pulse oximetry monitoring of children hospitalized with bronchiolitis who are not receiving supplemental oxygen.
Gender:
ALL
Ages:
2 months and above
Trial Updated:
06/03/2024
Locations: Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania
Conditions: Bronchiolitis Acute Viral
Register for Updates
Abbott DBS Post-Market Study of Outcomes for Indications Over Time
NCT04071847
Recruiting
The purpose of this international study is to evaluate long-term safety and effectiveness of Abbott deep brain stimulation (DBS) systems for all indications, including Parkinson's disease, essential tremor or other disabling tremor and dystonia.
Gender:
ALL
Ages:
All
Trial Updated:
05/24/2024
Locations: Allegheny General Hospital Department of Neurosurgery, Pittsburgh, Pennsylvania
Conditions: Movement Disorders, Parkinson Disease, Essential Tremor, Tremor, Dystonia, Primary Dystonia, Secondary Dystonia
Register for Updates